Bioqual (OTCMKTS:BIOQ) Releases Earnings Results

Bioqual (OTCMKTS:BIOQ) posted its quarterly earnings results on Thursday. The company reported $0.15 EPS for the quarter, Zacks reports. Bioqual had a negative return on equity of 1.73% and a negative net margin of 1.32%.

Bioqual Stock Performance

Shares of OTCMKTS BIOQ opened at $38.50 on Friday. The company has a market cap of $34.27 million, a price-to-earnings ratio of -55.00 and a beta of -0.19. Bioqual has a 12 month low of $33.00 and a 12 month high of $66.10. The stock has a 50-day moving average price of $38.51 and a two-hundred day moving average price of $40.47.

About Bioqual

Bioqual, Inc is a U.S.-based contract research organization specializing in preclinical immunology and pharmacology services for the biopharmaceutical industry. The company offers a range of in vivo and in vitro testing solutions designed to support vaccine development, immuno-oncology programs and other therapeutic modalities. Bioqual’s service portfolio encompasses assay development, safety and efficacy studies, biomarker analysis and specialized immunogenicity assessments.

Leveraging proprietary humanized animal models and nonhuman primate research platforms, Bioqual helps clients evaluate biological activity, toxicity and pharmacokinetics of investigational compounds.